Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
LAEKNA-B (02105.HK) announced that it intends to place a total of 17.636 million shares of the company, equivalent to about 4 ...
Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...
Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...
Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...
LOS ANGELES, November 20, 2024--Laekna, Inc. (2105.HK) ("Laekna"), a global biotech company focused on novel drug development for metabolic and cancer diseases, is pleased to announce a clinical ...
Laekna, Inc. (HK:2105) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall Street ...
LAEKNA-B (02105.HK) -0.580 (-3.737%) announced a share placing immediately after a 48% share surge yesterday (20th). Today ...